Precision Medicine Transforms Cardiovascular Care
'Precision medicine plays an important role here because if we treat the actual cause of a disease, we have a better chance of slowing its progression. But in the coming years, we must also go one step further by identifying patients who are at high risk of developing cardiovascular disease earlier and, in some cases, even treating them before clinical manifestations occur,' said Landmesser.
Precision medicine is gaining attention in routine cardiovascular care due to improvements in imaging technology, artificial intelligence (AI), and a growing understanding of genetic risk factors. Landmesser noted that these developments are enabling more personalized and effective treatment of the four most common cardiovascular conditions — coronary artery disease, atrial fibrillation (AF), heart failure, and valvular insufficiency — according to the German Heart Report.
Advanced Imaging
He cited one example in the use of optical coherence tomography (OCT) during coronary artery interventions. OCT provides high-resolution imaging, which is analyzed using AI, allowing for more precise guidance for the procedures.
A 2023 study showed that OCT-guided percutaneous coronary intervention (PCI) reduces procedural risk. In the study, 2487 patients with diabetes or complex coronary lesions were randomized to undergo either OCT-guided PCI (n = 1233) or angiography-guided PCI (n = 1254).
The primary efficacy endpoints were the post-PCI minimum stent area assessed by OCT after PCI and failure after 2 years, defined as a combination of cardiac death, target vessel myocardial infarction, or ischemia-related revascularization of the target vessel.
The minimum stent area after PCI was larger in the OCT group than in the angiography group (5.72 ± 2.04 mm² vs 5.36 ± 1.87 mm²; mean difference, 0.36 mm²; P < .001). Target vessel failure within 2 years occurred in 88 and 99 patients in the OCT and angiography groups. Stent thrombosis within 2 years occurred in 6 patients (0.5%) in the OCT group and 17 patients (1.4%) in the angiography group.
A 2024 meta-analysis further confirmed that intravascular imaging with OCT compared with angiography during coronary stent implantation improves both the safety and efficacy of PCI by reducing the risks for death, myocardial infarction, repeat revascularization, and stent thrombosis.
AI-Guided Ablation for AF
AI-driven approaches are also proving more effective in managing persistent and long-standing AF.
The TAILORED-AF study population (n = 370) was randomly assigned to a tailored ablation procedure, as detected by an AI algorithm, in addition to PVI (tailored arm, n = 187) or to a conventional PVI-only procedure (anatomical arm, n = 183).
The primary efficacy endpoint was freedom from documented AF with or without antiarrhythmic drugs 12 months after a single ablation procedure. One year post-procedure, the trial met its primary efficacy endpoint, which was achieved in 88% of patients in the tailored arm compared with 70% of patients in the anatomical arm ( P < .0001 for superiority).
The use of AI for reproducible and reliable identification of ablation target areas was evidently crucial for the observed advantage over the standard treatment, which relies on the subjective assessment of electrograms.
Targeted Genetic Therapies
Landmesser also highlighted the growing role of genetics in precision cardiology. Approximately 10% of the population has elevated levels of lipoprotein(a), which is a genetic cause of coronary artery disease and morphologic calcification of the aortic valve.
'We expect to have specific therapies available in the near future to address this genetic cause of coronary artery disease,' he said. Diagnosis requires only a one-time measurement of lipoprotein(a) levels.
Enhancing Diagnosis With AI
A study in the United Kingdom showed that using large language models significantly improved diagnostic accuracy, particularly for heart failure with preserved ejection fraction (HFpEF). The study found that HFpEF was clinically undiagnosed in 75% of the cases. Patients with undiagnosed HFpEF had a worse prognosis and represented a high-risk group.
'Perhaps AI can also help us make more reliable diagnoses in everyday practice,' Landmesser suggested.
Gene Editing
Looking ahead, Landmesser pointed to gene editing as a potential breakthrough in treating the root causes of cardiovascular diseases. In one study, 36 patients with transthyretin amyloidosis with cardiomyopathy received a single dose of nexiguran ziclumeran (nex-z) based on CRISPR-Cas9. The treatment led to a sustained 90% reduction in serum transthyretin levels over 12 months, meeting both efficacy and safety endpoints. This example demonstrates that, ideally, the cause can be treated causally as early as possible.
'Gene editing studies are primarily conducted in New Zealand, Australia, the United Kingdom, and the United States, and similar trials are expected to begin in Germany within the next year,' Landmesser noted. However, the regulatory approval timeline remains uncertain.
A Promising Outlook
'There is tremendous innovation in cardiology,' concluded Landmesser. 'With more precise imaging, AI-guided interventions, and deeper insights into genetic causes, we are moving toward safer, more effective, and individualized treatments — improving our ability to predict and manage cardiovascular risk.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
12 minutes ago
- Gizmodo
Ozempic Maker Novo Nordisk Freezes Hiring Amid Ongoing Struggles
No one stays on top forever. It's a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish pharmaceutical company has enacted a hiring freeze—the latest sign of a sinking financial outlook for the once-titan of the obesity treatment world. Reuters reported on the hiring freeze Wednesday. The company has faced numerous setbacks in recent months, including billions shaved off its stock market value and continued competition from cheaper, compounded versions of its blockbuster drug semaglutide. Though the freeze will apparently only apply to certain segments of the company, layoffs are likely not far off in the distance. 'We currently have a hiring freeze in non-business critical areas,' said Novo Nordisk in a statement to Reuters. Semaglutide is the active ingredient in Novo Nordisk's diabetes drug Ozempic and obesity medication Wegovy. It and similar compounds mimic the hormone GLP-1, which helps regulate insulin production and our appetite (among other functions). Though GLP-1 drugs have existed for two decades, semaglutide has proven more effective at helping people lose weight than diet and exercise alone, as well as other older medications. The approval of Wegovy in 2021 greatly reshaped the field of obesity medicine and earned plenty of money for Novo Nordisk. In 2024, the company reported about $42 billion dollars of revenue, driven by increasing sales of Wegovy and Ozempic (sometimes prescribed off-label for weight loss treatment). The company's success was so tremendous that it even helped bolster Denmark's local economy. But the company's meteoric rise has stumbled as of late for several reasons. For starters, it's no longer the only game in town, following the approval of Eli Lilly's tirzepatide for obesity (under the name Zepbound) in 2023. The drug, which combines GLP-1 with another weight-related hormone, is generally more effective than semaglutide, and people have steadily started to prefer it. Though Ozempic and Wegovy might still be more well known to the public, prescriptions of Zepbound in the U.S. now appear to be surpassing the former. Ozempic-Maker CEO Ousted Over Pharma Company's Rocky Market Downturn Novo Nordisk has also explicitly cited the emergence of the compounded drug market for GLP-1 therapy for its recent struggles. Compounded drugs are custom-made formulations of semaglutide and tirzepatide, often much cheaper, and produced by specialized pharmacies. The Food and Drug Administration has attempted to crack down on this industry, but many companies are still producing these drugs, and many people are still buying them. The fight over these compounded drugs has become so fierce that Novo Nordisk abruptly ended its newly formed partnership with telehealth company Hims in June. The company alleged that Hims was trying to deceptively market their compounded version of semaglutide over Wegovy to its users (Hims, for its part, has denied the accusation). These headwinds led Novo Nordisk to admit earlier this year that its projected sales growth in 2025 will fall short of past projections, which has since fueled further financial calamity. In May, the company fired its longtime CEO amid declining stocks. In July, investors wiped off $70 billion from the company's market value after it once again lowered its sales growth forecast for the remainder of the year. Sales of Wegovy and Ozempic do remain strong overall. And Novo Nordisk is developing other treatments intended to reclaim its throne in the obesity medicine field (including weight loss pills and drugs potentially more effective than any other treatment to date). But the company's fortunes are likely to worsen before they get better. Novo Nordisk Abruptly Ends Partnership with Hims, Claiming 'Sham Compounding' GLP-1 Drugs Departing CEO Lars Fruergaard Jørgensen stated in early August that the company, which currently employs nearly 80,000 people, will probably experience layoffs. The company's new CEO, Maziar Mike Doustdar, is also considering layoffs, according to a recent report from Danish TV2. This new era of obesity treatment isn't going anywhere anytime soon. But whether Novo Nordisk will remain the big dog on top is much more in question today than it would have been even just a few months ago.
Medscape
an hour ago
- Medscape
New First-Line Option for Advanced Bladder Cancer
The National Institute for Health and Care Excellence (NICE) has recommended the combination of enfortumab vedotin (Padcev, Astellas) with pembrolizumab (Keytruda, MSD) as a first-line option for adults with unresectable or metastatic urothelial cancer who are eligible for platinum-based chemotherapy. More than 1200 people in England are expected to benefit each year. Clinical experts described the combination therapy as a "step change" in bladder cancer management. Until now, treatment options for this patient group have seen little meaningful progress since the 1980s. Enfortumab vedotin is an antibody-drug conjugate consisting of an antibody targeting Nectin-4, a protein highly expressed in urothelial carcinoma cells. After binding, it causes the cells to release monomethyl auristatin E, resulting in cell death. Pembrolizumab, its combination partner, is a PD-1 inhibitor. High Disease Burden Urothelial cancer accounts for around 90% of bladder cancers, affecting more than 18,000 people annually in England. Prognosis is poor, with only 10% of patients with stage 4 disease surviving for 5 years or more. Current standard treatments include platinum-based chemotherapy ( cisplatin or carboplatin with gemcitabine), followed by avelumab maintenance therapy if the cancer has not progressed. However, only about 12% of patients see improvement with chemotherapy, underscoring the need for better options. Patient experts described living with metastatic urothelial cancer as "intensely challenging and emotionally exhausting', affecting work, travel, and physical activity. Action Bladder Cancer UK called the announcement a 'very welcome, and significant, step forward for this hard-to-treat cancer'. Clinical Evidence The recommendation in final draft guidance was supported by results from the phase 3 EV-302 trial, which enrolled 886 adults with untreated, unresectable, locally advanced, or metastatic urothelial cancer. Participants were randomly assigned in a 1:1 ratio to receive either enfortumab vedotin–pembrolizumab or standard chemotherapy. Enfortumab vedotin–pembrolizumab nearly doubled the median time to disease progression or death to 12.5 months, compared with 6.3 months for chemotherapy. Median overall survival was also improved, at 33.8 months versus 15.9 months with chemotherapy. Helen Knight, director of medicines evaluation at NICE, said the drug combination is 'highly promising and effective,' adding that these clinical trial results highlight the 'tremendous difference' it could make to the length and quality of people's lives. Cost and NHS Access Enfortumab vedotin is listed at £578 per 20 mg vial or £867 per 30 mg vial. Pembrolizumab costs £2630 per 100 mg vial, excluding VAT. The drugs will be supplied through confidential commercial arrangements with the NHS. NICE's appraisal committee applied a severity modifier, reflecting the high disease burden, and concluded that the therapy met acceptable cost-effectiveness thresholds. The treatment will be available immediately across the NHS in England, with funding required within 90 days of final publication of the guidance.
Fox News
an hour ago
- Fox News
AI tools could weaken doctors' skills in detecting colon cancer, study suggests
The benefits of artificial intelligence (AI) in the medical space are ever-growing, but evidence suggests it can also come with risks. A new study by European researchers investigated how AI can change the behavior of endoscopists when conducting a colonoscopy, and how their performance dips when not using AI. The research followed clinicians at four endoscopy centers in Poland participating in the ACCEPT (Artificial Intelligence in Colonoscopy for Cancer Prevention) trial, where AI tools for polyp detection were introduced at the end of 2021. Colonoscopies at these centers were randomly selected to be administered with or without AI assistance. The researchers gauged the quality of the colonoscopies by comparing the identification of tumors (also known as the adenoma detection rate, or ADR) three months before and three months after implementing the AI. From September 2021 to March 2022, 1,443 patients underwent non-AI-assisted colonoscopies before and after the introduction of AI. The study found that the tumor detection rate decreased "significantly," going from 28.4% before AI exposure to 22.4% after AI exposure. The findings were published in the journal Lancet Gastroenterology and Hepatology. Per the researchers' analysis, exposure to AI, patient gender and age were "independent factors" associated with the tumor identification rate. The researchers concluded that "continuous exposure to AI might reduce the ADR of standard non-AI-assisted colonoscopy, suggesting a negative effect on endoscopist behavior." Harvey Castro, M.D., an emergency physician and specialist in AI and healthcare based in Texas, said he considers this study an "important piece of work." "This study highlights a paradox in medicine: Artificial intelligence can help us detect cancer, but it may also weaken the doctor's own ability to see what matters when the tool is not available," he said in an interview with Fox News Digital. Castro emphasized that even a 1% change can affect colon cancer survival for "thousands of patients," which makes the 6% drop in detection rates significant. "Even small changes in adenoma detection can shift cancer outcomes," he said. "A reduction of a few percentage points is meaningful at a population level." The expert recommends integrating AI "wisely" instead of avoiding it all together. "As a physician futurist, I believe artificial intelligence is one of the most powerful tools we have for improving detection and saving lives," Castro said. "At the same time, this study reminds us of a simple truth: Medicine is still a human profession. The doctor's eye, judgment and pattern recognition remain irreplaceable." Castro commented that the right path forward with AI in medicine is balance, designing it to strengthen clinicians instead of weakening. For more Health articles, visit "That requires training, oversight and intentional design," he said. "The best future is one where technology and humanity work side-by-side, doctor plus machine, ensuring patients get the safest and most effective care possible."
